Halozyme Therapeutics HALO Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's change in AR?
- Halozyme Therapeutics (HALO) reported change in AR of $19.55M in Q1 2026.
- How has Halozyme Therapeutics's change in AR changed year-over-year?
- Halozyme Therapeutics's change in AR increased by 609.8% year-over-year, from -$3.83M to $19.55M.
- What is the long-term trend for Halozyme Therapeutics's change in AR?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's change in AR has grown at a 108.7% compound annual growth rate (CAGR), from -$6.76M to $128.06M.
- What does change in AR mean?
- Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.